| Autor: |
Bertlich, M., Bertlich, I., Plümacher, N., Hadaschik, E., Enk, A., Hoffmann, J. H. O. |
| Předmět: |
|
| Zdroj: |
Journal of the European Academy of Dermatology & Venereology; Jan2024, Vol. 38 Issue 1, pe74-e76, 3p |
| Abstrakt: |
A retrospective cohort study conducted at the University of Heidelberg compared the treatment outcomes of conventional immunosuppressants (CI) alone versus CI combined with high-dose intravenous immunoglobulins (IVIg) in patients with autoimmune bullous diseases (AIBD). The study found that the addition of IVIg to CI significantly prolonged the time-to-treatment escalation (TTE) and reduced the chance of treatment escalation after 1, 2, and 3 years. However, there was no significant difference in time-to-full remission or cumulative steroid dose between the two treatment groups. The study suggests that IVIg may help sustain remission in recalcitrant AIBD, but further prospective studies are needed to confirm these findings. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text